Ethyl 3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate

We are Ethyl 3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate CAS:101987-86-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Ethyl 3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate
CAS.NO:101987-86-4
Synonyms:Ethyl 3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate
Benzenepropanoic acid, 3-chloro-2,4,5-trifluoro-β-oxo-, ethyl ester
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 325.3±42.0 °C at 760 mmHg
Melting Point 80-83ºC
Molecular Formula C11H8ClF3O3
Molecular Weight 280.628
Flash Point 130.0±17.0 °C
 
Specification:
Appearance:White to off-white solid
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Sitafloxacin and Delafloxacin.

Ethyl 3-(3-chloro-2,4,5-trifluorophenyl)-3-oxopropanoate


Related News: The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured.(R, E) -etil 5 – ([1,1'-bifenil] -4-il) -4 – ((terc-butoxicarbonil) amino) -2-metilpent-2-enoato CAS:149709-59-1 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea CAS:796848-79-8 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.82357-48-0 According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.

Related Products
Product Name
N-[2-(diethylamino)ethyl]-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide View Details
4-methylaminophenol sulfate View Details
2-Anilino-6-dibutylamino-3-methylfluoran View Details
2-Bromotoluene manufacturer Dipeptide-2 manufacturer (2S)-trans-3-Amino-2-methyl-4-oxoazetidine-1-sulphonic acid manufacturer Bis(2-chloroethyl)amine hydrochloride manufacturer Dibenzo[b,d]furan-3-ylboronic acid manufacturer